Literature DB >> 10427612

Alcohol dependence and hospitalization in schizophrenia.

L B Gerding1, L A Labbate, M O Measom, A B Santos, G W Arana.   

Abstract

Treatment of schizophrenia is often complicated by substance abuse. We report here findings of a retrospective study evaluating readmission rates of patients meeting DSM IV criteria comorbid for schizophrenia and alcohol or drug dependence treated with depot haloperidol or fluphenazine over a 2-year period. During the study period, 14 of the 26 (54%) male veteran patients were admitted to the VAMC, Charleston; 46% of patients met criteria for alcohol, marijuana or cocaine dependence. Patients with alcohol dependence appeared to be at highest risk for hospital admission (p < 0.05). Moreover, patients with alcohol dependence had longer hospital stays (p < 0.05) than patients without alcohol dependence. Marijuana or cocaine dependence was slightly, but not statistically more common among admitted patients. Marijuana or cocaine dependence did not predict length of stay or number of admissions. Alcohol dependence may be an important factor in schizophrenic exacerbation, and may be an important target for treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427612     DOI: 10.1016/s0920-9964(98)00177-7

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

Review 1.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 2.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

3.  Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.

Authors:  Leslie Citrome; Stephanie S O'Malley; David McDonnell; Ying Jiang; Adam C Simmons; Mark P Berry; Lauren E Dipetrillo
Journal:  Innov Clin Neurosci       Date:  2019-05-01

4.  Ethanol sensitization in a neurodevelopmental lesion model of schizophrenia in rats.

Authors:  Susan K Conroy; Zachary Rodd; R Andrew Chambers
Journal:  Pharmacol Biochem Behav       Date:  2006-08-28       Impact factor: 3.533

5.  Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.

Authors:  Ismene L Petrakis; Charla Nich; Elizabeth Ralevski
Journal:  Schizophr Bull       Date:  2006-08-03       Impact factor: 9.306

6.  Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.

Authors:  Sarah L Desmarais; Richard A Van Dorn; Brian G Sellers; M Scott Young; Marvin S Swartz
Journal:  Psychol Addict Behav       Date:  2012-12-31

7.  Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.

Authors:  Mary F Brunette; Robert E Drake; Haiyi Xie; Gregory J McHugo; Alan I Green
Journal:  Schizophr Bull       Date:  2006-06-16       Impact factor: 9.306

Review 8.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

9.  Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.

Authors:  Ismene L Petrakis; Stephanie O'Malley; Bruce Rounsaville; James Poling; Colette McHugh-Strong; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

10.  Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis.

Authors:  Xiaoqin Yang; Guiping Wang; Yaodong Wang; Xia Yue
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-25       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.